CureVac
Moritz Thran is a seasoned research professional with extensive experience in mRNA-based therapeutics and protein interactions. Since June 2015, Moritz has served as a Senior Research Scientist at CureVac AG, after progressing from the role of Scientist in Enabling Technologies. Prior to this, a postdoctoral researcher position at the Max-Planck-Institute for Developmental Biology was held from September 2013 to May 2015, where research focused on protein-protein interactions and mRNA decay associated protein complexes. Additionally, experience as a Clinical Research Associate at Winicker Norimed and as a PhD student at FAU Erlangen-Nürnberg further contributed to a solid foundation in biological research, culminating in a Diplom in Biology from FAU Erlangen-Nürnberg in 2008.
This person is not in any teams
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.